SAN DIEGO, CA--(Marketwire - June 01, 2009) - Lpath, Inc. (OTCBB: LPTN), the category leader in bioactive-lipid-targeted therapeutics, will hold a conference call on Thursday, June 4, 2009 at 4:30 p.m. Eastern time to provide a first quarter business review and clinical update.
Lpath President and CEO Scott Pancoast will host the presentation, followed by a question-and-answer period.
To participate in the call, dial the appropriate number 5-10 minutes prior to the start time, request the Lpath conference call, and provide the conference ID shown below.
Date: Thursday, June 4, 2009 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Dial-In Number: 1-800-862-9098 International: 1-785-424-1051 Conference ID#: 7LPATH Internet simulcast and replay: http://viavid.net/dce.aspx?sid=000065B8 If you have any difficulty connecting with the conference call, please contact the Liolios Group at 949-574-3860.
A telephone replay of the call will be available from 7:30 p.m. Eastern time on the same day until June 11, 2009 by dialing the following numbers (no passcode required):
Toll-free replay number: 1-800-374-1375 International replay number: 1-402-220-0682
About Lpath
Lpath, Inc., headquartered in San Diego, is the category leader in bioactive-lipid-targeted therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP™, an antibody against Sphingosine-1-Phosphate (S1P), is currently in a Phase 1 clinical trial in cancer and also holds promise against multiple sclerosis and various other disorders. ASONEP is being developed with the support of partner Merck-Serono as part of a worldwide exclusive license. A second product candidate, iSONEP™ (the ocular formulation of the S1P antibody), has demonstrated superior results in various preclinical models of age-related macular degeneration (AMD) and retinopathy and is in a Phase 1 clinical trial in wet-AMD patients. Lpath’s third product candidate, Lpathomab™, is an antibody against Lysophosphatidic Acid (LPA), a key bioactive lipid that has been long recognized as a valid disease target (cancer, neuropathic pain, AMD, fibrosis). The company’s unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2™ drug-discovery engine, which the company is leveraging as a means to expand its pipeline. For more information, go to www.Lpath.com
Lpath Contacts:
Lpath, Inc.
Scott R. Pancoast
President & CEO
858-678-0800 x104
Email Contact
Lpath Investor Relations
Liolios Group, Inc.
Ron Both
949-574-3860
Email Contact
